✨ Medicines Consent Notices




834 NEW ZEALAND GAZETTE No. 33

Note: This consent is valid for 2 years from the 25th day of February 1999.

Dated this 11th day of March 1999.

GILLIAN GREW, Chief Advisor, Regulation and Safety (Acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go2081

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Pseudoephedrine hydrochloride 60mg Capsule, liquid filled R P Scherer Holdings Pty Limited, Braeside, Victoria, Australia Dimetapp Sinus Liquid Caps
Triamcinolone acetonide 0.1%w/w Paste, topical Taro Pharmaceuticals Inc., Bramelea, Ontario, Canada Oracort
Aciclovir 5%w/w Ointment, topical Taro Pharmaceuticals Inc., Bramelea, Ontario, Canada Viraban

Dated this 11th day of March 1999.

GILLIAN GREW, Chief Advisor, Regulation and Safety (Acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go2080

Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Lamotrigine 25mg Tablet, chewable/dispersible Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom; Glaxo Wellcome Australia Limited, Boronia, Victoria, Australia; and Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Lamictal
Lamotrigine 5mg Tablet, chewable/dispersible Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom; and Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Lamictal
Lamotrigine 50mg, 100mg, 200mg Tablets, chewable/dispersible Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom; and Glaxo Wellcome Australia Limited, Boronia, Victoria, Australia Lamictal
Nimodipine 30mg Tablet, film coated Bayer AG., Leverkusen, Germany Nimotop
Nimodipine 0.2mg/mL Infusion, solution Bayer AG., Leverkusen, Germany Nimotop
Naltrexone hydrochloride 50mg Tablet, film coated Du Pont Merck Pharmaceuticals Co., Garden City, New York, United States of America Re Via
Paclitaxel 6 mg/mL Infusion, concentrate Bristol-Caribbean Inc., Mayaguez, Puerto Rico Taxol

Dated this 11th day of March 1999.

GILLIAN GREW, Chief Advisor, Regulation and Safety (acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go2078



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1999, No 33


NZLII PDF NZ Gazette 1999, No 33





✨ LLM interpretation of page content

πŸ₯ Corrigendum: Consent to the Distribution of a New Medicine (continued from previous page)

πŸ₯ Health & Social Welfare
11 March 1999
Medicines Act 1981, Abacavir sulphate, Ziagen, Glaxo Wellcome Operations
  • GILLIAN GREW, Chief Advisor, Regulation and Safety (Acting)

πŸ₯ Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
11 March 1999
Medicines Act 1981, Pseudoephedrine hydrochloride, Triamcinolone acetonide, Aciclovir, Dimetapp Sinus Liquid Caps, Oracort, Viraban
  • GILLIAN GREW, Chief Advisor, Regulation and Safety (Acting)

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
11 March 1999
Medicines Act 1981, Lamotrigine, Nimodipine, Naltrexone hydrochloride, Paclitaxel, Lamictal, Nimotop, Re Via, Taxol
  • GILLIAN GREW, Chief Advisor, Regulation and Safety (acting)